AB Science Presents Initial Phase 1 Data for AML Treatment

Initial Results from Phase 1

AB Science has released the initial results from Phase 1 for its AB8939 treatment, in combination with venetoclax, aimed at treating refractory or relapsed acute myeloid leukemia (AML). According to the company, the results show a disease control rate of 100% and a partial response rate also of 100%, including one patient who achieved complete remission. These results were observed after the first 14-day treatment cycle in three patients who were on their third or fourth line of treatment, two of whom had previously shown disease progression under venetoclax combined with other chemotherapies. The company plans to complete this Phase 1 and initiate an extension study with about fifteen patients.

AML Characterized as Highly Lethal

Acute myeloid leukemia is described by the company as the most lethal form of leukemia in humans, with disease heterogeneity influenced by specific genetic factors. The company notes that about 70% of patients experience a relapse and succumb to the disease. AB Science emphasizes that genetic mutations such as TP53, NRAS, and KRAS are associated with poor prognoses. AB8939 is highlighted for its mechanisms of action aimed at circumventing typical resistances encountered in chemotherapy, specifically targeting cancer stem cells and inhibiting the ALDH enzyme.

Future Development Plans

AB Science plans to continue the development of the AB8939 and venetoclax combination for AML, with ongoing discussions with health authorities such as the FDA and EMA to potentially advance towards registration studies. The goal is to position this combination as a first and third line of treatment, particularly for patients with genetic abnormalities. The company estimates that the potential market for these treatments of refractory or recurrent AML exceeds 2 billion euros per year. Intellectual property rights for AB8939 in this area are secured until 2036, with a possibility of extension.